Randomized Trial: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
9 Nov, 2018 | 02:55h | UTCCommentaries: Among heart attack survivors, drug reduces chances of second heart attack or stroke – University of Colorado Anschutz Medical Campus (free) AND Alirocumab Linked to Lower Risk for Recurrent Ischemic CV Events – NEJM Journal Watch (free)
“An estimated 49 patients would need to be treated for 4 years to prevent one CV event.” (from NEJM Journal Watch)